TITLE:
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

CONDITION:
HIV Infections

INTERVENTION:
Saquinavir

SUMMARY:

      To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine
      plus lamivudine.
    

DETAILED DESCRIPTION:

      A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus
      lamivudine until the completion of the analysis after at least 4 weeks of therapy.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV antibody positive.

          -  CD4 count >= 150 and <= 500 cells/mm3.

        Exclusion Criteria

        Prior Medication:

        Excluded:

          -  Prior antiretroviral therapy.

          -  Prior protease inhibitor therapy.
      
